Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
371. |
ECCT/22/12/03 | heredERA A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO + TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER |
Principal Investigator(s) 1. Mansoor Saleh 2. Fredrick Chite Asirwa Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
12-04-2023 |
View |
372. |
ECCT/23/01/01 | PROHER A PHASE IIIB, MULTINATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE PATIENT PREFERENCE FOR HOME ADMINISTRATION OF FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS ADMINISTRATION IN PARTICIPANTS WITH EARLY OR LOCALLY ADVANCED/ INFLAMMATORY HER2-POSITIVE BREAST CANCER |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Mansoor Saleh Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
12-05-2023 |
View |
373. |
ECCT/23/01/02 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Ogutu Bernhards Ragama Site(s) in Kenya 1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county) 2. Gertrude\'s Children Hospital (Nairobi City county) 3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds, (Siaya county) 4. Kombewa CRC (Kisumu county) |
24-05-2023 |
View |
374. |
ECCT/23/01/03 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Githanga Githanga Nyokabi Site(s) in Kenya 1. Gertrude\'s Children Hospital (Nairobi City county) 2. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county) 3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds (Siaya county) 4. Kombewa CRC (Kisumu county) |
19-06-2023 |
View |
375. |
ECCT/23/01/04 | ACTIV-2d/A5407 A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19 |
Principal Investigator(s) 1. Lucas Tina Otieno Site(s) in Kenya 1. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county) 2. Victoria Biomedical Research Institute, (Kisumu county) 3. Kenya Medical Research Institute/Walter Reed Project (Kericho county) 4. Kenyatta National Hospital (Nairobi City county) 5. Ahero Clinical Trials Unit, (Kisumu county) 6. KEMRI CCR – BUTERE SITE (Kakamega county) |
01-06-2023 |
View |
376. |
ECCT/23/01/05 | IMPALA Study Efficacy, Safety and Effectiveness of Injectable Cabotegravir/Rilpivirine in Improving HIV-1 Control in Sub-Saharan Africa: A Pragmatic Phase 3b Open-Label Randomized Controlled Trial |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Kenyatta National Hospital (Nairobi City county) 2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) |
14-03-2023 |
View |
377. |
ECCT/23/01/06 | FENHANCE A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS CSF BIOMARKER SUBSTUDY ASSOCIATED WITH A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY (GN41851) TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS |
Principal Investigator(s) 1. Mansoor Saleh Site(s) in Kenya Aga Khan University, Nairobi |
13-06-2023 |
View |
378. |
ECCT/23/01/08 | SKY-06 A PHASE II/III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya International Cancer Institute |
28-05-2023 |
View |
379. |
ECCT/23/02/01 | Hibiscus Kid\'s Study A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease |
Principal Investigator(s) 1. Videlis Nduba 2. Walter Otieno 3. Isaac Tsikhutsu Site(s) in Kenya 1. AHERO CLINICAL TRIALS UNIT (Kisumu county) 2. KEMRI-Walter Reed-Kericho (Kericho county) 3. KEMRI: Siaya Clinical Research Annexe (Kisumu county) 4. Kombewa Clinical Research Centre (Kisumu county) |
14-06-2023 |
View |
380. |
ECCT/23/02/02 | KARISMA An adaptive, randomized, active-controlled, open-label, sequential cohort, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of intravenous cipargamin (KAE609) in adult and pediatric participants with severe Plasmodium falciparum malaria(KARISMA – KAE609’s Role in Severe Malaria) |
Principal Investigator(s) 1. Simon Kariuki Site(s) in Kenya KEMRI-CGHR, |
01-06-2023 |
View |